Lv32
250 积分 2025-03-25 加入
SHR2554, an EZH2 inhibitor, in relapsed or refractory mature lymphoid neoplasms: a first-in-human, dose-escalation, dose-expansion, and clinical expansion phase 1 trial
15分钟前
已完结
Structural classification of EZH2 inhibitors and prospects for the treatment of tumor: a review
2个月前
已完结
Targeting the “Undruggable”: Small-Molecule Inhibitors of Proliferating Cell Nuclear Antigen (PCNA) in the Spotlight in Cancer Therapy
2个月前
已完结
Thioguanine-Coordinated Assembly for Synthetic Lethality of Colorectal Cancer with Defective Mismatch Repair
3个月前
已完结
Dual-target EZH2 inhibitor: latest advances in medicinal chemistry
3个月前
已完结
Histone Deacetylase and Enhancer of Zeste Homologue 2 Dual Inhibitors Presenting a Synergistic Effect for the Treatment of Hematological Malignancies
3个月前
已完结
Design, Synthesis, and Biological Evaluation of a Potent Dual EZH2–BRD4 Inhibitor for the Treatment of Some Solid Tumors
3个月前
已完结
Development of a Prognostic Risk Model Based on Oxidative StressRelated Genes for Platinum-Resistant Ovarian Cancer Patients
3个月前
已完结
皖公网安备34019202002308
